Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Markets & Finance

RBC Captial Ups Trimeris to 'Outperform'


RBC Capital upgraded Trimeris (TRMS) to outperform from sector perform.

Analyst Todd Nelson says he's very encouraged by the news that Swiss drug maker Roche's HIV drug, T-20, lowered blood levels of the virus significantly more than a combination of drugs that did not include T-20.

Nelson thinks the FDA will look favorably upon this drug, and believes Trimeris -- which will market the drug in the U.S. -- and Roche remain on track with their T-20 New Drug Application. He also believes this data will support a NDA filing in the second half of 2002, and has the potential for late 2002 to early 2003 FDA approval.

Nelson sees $329.7 million in worldwide 2003 T-20 sales. He recommends the aggressive purchase of Trimeris today today on the positive clinical outcome. Nelso maintains his $54 target. He sees a $4.89 2002 loss, and a $1.49 2003 loss.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus